Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial
- 31 October 2002
- journal article
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 56 (4) , 488-495
- https://doi.org/10.1016/s0016-5107(02)70431-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Complications of Diagnostic and Therapeutic Ercp: A Prospective Multicenter StudyAmerican Journal of Gastroenterology, 2001
- Prevention of post-ERCP pancreatitisGastrointestinal Endoscopy, 2000
- ERCP economicsGastrointestinal Endoscopy, 1999
- Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication studyGastrointestinal Endoscopy, 1999
- Gabexate for the Prevention of Pancreatic Damage Related to Endoscopic Retrograde CholangiopancreatographyNew England Journal of Medicine, 1996
- Complications of Endoscopic Biliary SphincterotomyNew England Journal of Medicine, 1996
- Endoscopic sphincterotomy complications and their management: an attempt at consensusGastrointestinal Endoscopy, 1991
- Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitisGastrointestinal Endoscopy, 1991
- Acute pancreatitis: value of CT in establishing prognosis.Radiology, 1990
- Prevention of Pancreatic Reactions by Bolus Somatostatin Administration in Patients Undergoing Endoscopic Retrograde Cholangio-Pancreatography and Endoscopic SphincterotomyHormone Research, 1988